Company news
ProQR Therapeutics N.V. news in 2022
ProQR Therapeutics N.V.'s news releases, calls and decks from 2022, newest first.
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
December 21, 2022
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
November 13, 2022
ProQR Announces Third Quarter 2022 Operating and Financial Results
November 8, 2022
ProQR Announces Second Quarter 2022 Operating and Financial Results
August 3, 2022
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
May 31, 2022
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
May 8, 2022
ProQR Announces First Quarter 2022 Operating and Financial Results
May 4, 2022
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
April 12, 2022
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
March 6, 2022
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
February 23, 2022
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
February 10, 2022
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
January 3, 2022
Decks in 2022
- Corporate Update (December 2022)
Corporate update · 34 slides · Dec 23, 2022
- Corporate Update (April 2022)
Corporate update · 36 slides · Apr 13, 2022